Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their use

Details for Australian Patent Application No. 2005208869 (hide)

Owner Transform Pharmaceuticals, Inc.

Inventors Almarsson, Orn; Zhang, Zhong; Chen, Hongming

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-B-2005208869

PCT Pub. Number WO2005/072343

Priority 10/766,631 28.01.04 US

Filing date 27 January 2005

Wipo publication date 11 August 2005

Acceptance publication date 17 February 2011

International Classifications

A61K 31/56 (2006.01) - Compounds containing cyclopenta[a]hydrophenanthrene ring systems

A61K 9/10 (2006.01) Medicinal preparations characterised by special physical form - Dispersions

A61K 31/05 (2006.01)

A61K 31/74 (2006.01) - Synthetic polymeric materials

Event Publications

21 September 2006 PCT application entered the National Phase

  PCT publication WO2005/072343 Priority application(s): WO2005/072343

17 February 2011 Application Accepted

  Published as AU-B-2005208869

10 March 2011 Corrigenda

  Applications Accepted - Name Index Under the name Transform Pharmaceuticals, Inc., Application No. 2005208869, under INID (54) correct the title to read Aqueous Pharmaceutical Compositions of 2,6-Diisopropylphenol (propofol) and Their Uses

19 May 2011 Assignment before Grant

  Transform Pharmaceuticals, Inc. The application has been assigned to Centocor Ortho Biotech Inc.

16 June 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005208871-Enhancement of ampakine-induced facilitation of synaptic responses by cholinesterase inhibitors

2005208847-Policy-based admission control and bandwidth reservation for future sessions